文献速递胸部肿瘤放疗放疗物理与技术

胸部放疗相关静息心率升高与心动过速及其心血管结局意义

Escalation of Resting Heart Rate and Tachycardia as a Response to Thoracic Radiotherapy: Implications for Cardiovascular Outcomes after Radiotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-10-22

该回顾性研究分析了110例局部晚期非小细胞肺癌患者接受根治性放化疗期间及之后的系列静息心率测量,发现放疗期间静息心率中位数从81.5次/分显著升至放疗结束时的93次/分,且心动过速发生率从基线11.2%升至放疗后1个月的36.5%。较高的窦房结平均剂量与心率升高、恢复延迟及持续性心动过速相关,放疗期间及之后的心率升高与发生心律失常的 odds 增加相关。

要点

  • 放疗期间静息心率中位数从81.5次/分显著升至93次/分,12个月后30.6%患者仍升高。
  • 心动过速发生率从基线11.2%升至放疗后1个月36.5%。
  • 较高窦房结平均剂量与心率升高、恢复延迟及持续性心动过速相关。

核心结论

  • 非小细胞肺癌胸部放疗期间及之后可观察到静息心率升高和心动过速,且与较高窦房结平均剂量相关。
  • 心率升高与发生新发心律失常的风险增加相关,提示心率可能作为亚临床心脏损伤的无创生物标志物。

研究设计与样本

  • 回顾性分析2017-2022年间连续接受根治性放化疗序贯度伐利尤单抗的局部晚期非小细胞肺癌患者的系列静息心率测量。
  • 共纳入110例患者,56.4%有既往心脏病,中位随访33.6个月,中位年龄70.4岁。
  • 提取心脏及17个心脏亚结构的放疗剂量,采用广义加性混合模型和回归分析评估关联。

主要发现

  • 放疗期间静息心率中位数从81.5次/分显著升至放疗结束时的93次/分(p < 0.0001),放疗后12个月30.6%患者仍升高。
  • 心动过速发生率从基线11.2%升至放疗后1个月36.5%(p < 0.0001)。
  • 调整合并症后,较高窦房结平均剂量与较高的心率升高、心率恢复延迟及持续性心动过速相关(均p < 0.05)。
  • 放疗期间心率升高(β = 0.23, p = 0.005)和放疗后心率升高(β = 13.49, p = 0.049)以及放疗期间心动过速发作与发生心律失常的 odds 增加相关(OR, 2.97, 95% CI, 1.17-7.52, p = 0.022)。

临床怎么用

  • 对接受胸部放疗的非小细胞肺癌患者,可考虑常规监测静息心率以早期发现亚临床心脏损伤。
  • 在制定放疗计划时,关注窦房结受照剂量,探索主动性剂量降低策略以减轻治疗后心律失常风险。

局限性

  • 本研究为回顾性分析,样本量有限(110例),结果需前瞻性研究验证。
  • 常规心率监测和窦房结剂量降低策略的潜在获益尚需前瞻性研究检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac toxicity is a well-recognized, but poorly understood complication of radiotherapy (RT). In non-oncological settings, there is an established relationship between resting heart rate and cardiovascular health. OBJECTIVES: To study the incidence and pattern of resting heart rate (rHR) as an early sign of cardiotoxicity among patients with non-metastatic non-small cell lung cancer (NSCLC) treated with RT. METHODS: We retrospectively analyzed serial rHR measurements of consecutive patients with locally advanced NSCLC treated with definitive chemoradiation (CRT) over 6-7 weeks of daily radiation treatments followed by immunotherapy (durvalumab) between 2017-2022. Radiation dose to the heart and 17 cardiac substructures were extracted. Associations between heart rate elevation, tachycardia, cardiac substructure dose and outcomes were evaluated using generalized additive mixed models (GAMMs) and regression analysis. RESULTS: We identified 110 patients, 56.4% with pre-existing heart disease. Median follow-up was 33.6 months. Median age was 70.4 years. Median rHR increased significantly during RT, rising from 81.5 bpm to 93 bpm at end of RT (p < 0.0001), remaining elevated in 30.6% of patients 12 months post-RT. Tachycardia incidence rose from 11.2% at baseline to 36.5% at 1-month post-RT (p < 0.0001). After adjusting for comorbidities, higher mean sinoatrial node (SAN) dose was associated with higher rHR elevation, delayed HR recovery and persistent tachycardia (all p < 0.05). Higher rHR during and after RT (β = 0.23, p = 0.005, and β = 13.49, p = 0.049, respectively), as well as the incidence of tachycardia episodes during RT were associated with increased odds of developing an arrhythmia (OR, 2.97, 95% CI, 1.17-7.52, p = 0.022). CONCLUSIONS: Elevated rHR and tachycardia are observed during and after RT for NSCLC and are associated with higher mean SAN dose. HR elevation was associated with increased risk of de novo arrhythmias, suggesting that heart rate may represent a non-invasive biomarker of subclinical cardiac injury. Prospective studies might be warranted to test the potential of routine HR monitoring and proactive dose reductions to the SAN to enable early detection and help mitigate the risk of post-treatment arrhythmia.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ajdari A, Bobic M, Ciausu C, et al. Escalation of Resting Heart Rate and Tachycardia as a Response to Thoracic Radiotherapy: Implications for Cardiovascular Outcomes after Radiotherapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 42913865. doi:10.1016/j.ijrobp.2026.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。